BRAF and melanoma: Specifically, the effects of ERβ agonists were assessed on the proliferation of the following human melanoma cell lines: IGR-39 cells (expressing almost undetectable levels of ERβ), A375 and WM1552 cells (expressing ERβ and harboring the BRAF V600E mutation), and WM115 cells (expressing ERβ and harboring the rare BRAF V600D mutation).